AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11192323 — intervention group
Group type: COMPARATOR
Intervention: TNF2 allele presence in primary sclerosing cholangitis patients (A at position -308)
Number of subjects: 139
Study 11192323 — intervention group
Group type: COMPARATOR
Intervention: TNF2 allele presence in auto-immune hepatitis patients
Number of subjects: 139
Study 11192323 — intervention group
Group type: COMPARATOR
Intervention: IL-10 and TGFbeta1 polymorphisms
Number of subjects: 139
Study 11192323 — intervention group
Group type: COMPARATOR
Intervention: Genotype association with Child's class in primary biliary cirrhosis
Number of subjects: 139
Study 8791185 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 43
Study 8791185 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 43
Study 1325167 — intervention group
Group type: EXPERIMENTAL
Intervention: Timetabled visiting by Health Visitor Assistants (HVAs)
Number of subjects: 0
Study 1325167 — intervention group
Group type: COMPARATOR
Intervention: No timetabled visiting (Control group)
Number of subjects: 0
Study 1325167 — intervention group
Group type: EXPERIMENTAL
Intervention: Timetabled visiting by HVAs
Number of subjects: 0
Study 6712539 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet with a high ratio of polyunsaturated-to-saturated fatty acids
Number of subjects: 38
Study 6712539 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to original diet
Number of subjects: 38
Study 30968210 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs with adequate allocation concealment (43 out of 261, 16.47%)
Number of subjects: 6997
Study 30968210 — intervention group
Group type: EXPERIMENTAL
Intervention: Jadad Quality Scale evaluation
Number of subjects: 6997
Study 29907335 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (weekly sessions for 8 weeks)
Number of subjects: 120
Study 29907335 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy exercise program (8-week program)
Number of subjects: 120
Study 26951389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle-exercise group (EX)
Number of subjects: 30
Study 26951389 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group (CON)
Number of subjects: 30
Study 26951389 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity levels (Long-Term Phase)
Number of subjects: 30
Study 24983262 — intervention group
Group type: EXPERIMENTAL
Intervention: Djembe drumming sessions (40 minutes)
Number of subjects: 2
Study 22876442 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Linggui Zhugan decoction combined with short-term very low calorie diets (VLCDs)
Number of subjects: 85
Study 22876442 — intervention group
Group type: COMPARATOR
Intervention: Basic weight-reduction treatment (Control group)
Number of subjects: 85
Study 20213672 — intervention group
Group type: EXPERIMENTAL
Intervention: TETRA handset
Number of subjects: 53
Study 20213672 — intervention group
Group type: COMPARATOR
Intervention: Sham control signals
Number of subjects: 53
Study 18032149 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb dexterity training
Number of subjects: 15
Study 18032149 — intervention group
Group type: COMPARATOR
Intervention: Lower limb training
Number of subjects: 15
Study 15860240 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes passport intervention
Number of subjects: 150
Study 15860240 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 12537209 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Fontan operation
Number of subjects: 40
Study 10793433 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT), n = 25
Number of subjects: 49
Study 10793433 — intervention group
Group type: COMPARATOR
Intervention: No Therapy (NT), n = 24
Number of subjects: 49
Study 8656502 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 150 mg every 12 hours plus zidovudine
Number of subjects: 223
Study 8656502 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 300 mg every 12 hours plus zidovudine
Number of subjects: 223
Study 8656502 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine monotherapy
Number of subjects: 223
Study 1658975 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg once daily
Number of subjects: 367
Study 1658975 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily
Number of subjects: 367
Study 1658975 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 367
Study 6628006 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV)
Number of subjects: 309
Study 6628006 — intervention group
Group type: COMPARATOR
Intervention: Volume‐cycled ventilator (VCV)
Number of subjects: 309
Study 29112048 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-residue diet (LRD)
Number of subjects: 0
Study 29112048 — intervention group
Group type: COMPARATOR
Intervention: Clear liquid diet (CLD)
Number of subjects: 0
Study 28994359 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating ≥5 servings of fruits and vegetables (F&V) per day
Number of subjects: 279
Study 28994359 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about wasting food when serving F&V
Number of subjects: 279
Study 28994359 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving one's own car to the store
Number of subjects: 279
Study 26329397 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 5543
Study 26329397 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 5543
Study 26329397 — intervention group
Group type: COMPARATOR
Intervention: Skeletal-related events (SREs)
Number of subjects: 5543
Study 23945841 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web-based training module
Number of subjects: 40
Study 23945841 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 40
Study 22569730 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention consisting of 15 preconception health education sessions
Number of subjects: 77
Study 22569730 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 77
Study 22569730 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 77
Study 21284250 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro‐Argin formula whitening dentifrice (test group)
Number of subjects: 92
Study 21284250 — intervention group
Group type: COMPARATOR
Intervention: Original Pro‐Argin formula dentifrice (control group)
Number of subjects: 92
Study 17377691 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% Triclosan varnish applied twice a year (every half year) for one year.
Number of subjects: 606
Study 17377691 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 606
Study 15704508 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 additional therapy sessions (over four weeks) comprising exercises aimed at improving lateral weight transference in sitting delivered by trained physiotherapy assistants
Number of subjects: 35
Study 15704508 — intervention group
Group type: COMPARATOR
Intervention: Usual care including physiotherapy
Number of subjects: 35
Study 11897208 — intervention group
Group type: EXPERIMENTAL
Intervention: niacin/lovastatin 500/10 mg
Number of subjects: 814
Study 11897208 — intervention group
Group type: EXPERIMENTAL
Intervention: niacin/lovastatin 1,000/20 mg
Number of subjects: 814
Study 11897208 — intervention group
Group type: EXPERIMENTAL
Intervention: niacin/lovastatin 1,500/30 mg
Number of subjects: 814
Study 11897208 — intervention group
Group type: EXPERIMENTAL
Intervention: niacin/lovastatin 2,000/40 mg
Number of subjects: 814
Study 9854276 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery therapy for 6 weeks
Number of subjects: 50
Study 9854276 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery therapy
Number of subjects: 50
Study 9854276 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 8548055 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose progesterone (0.714 mg.kg‐1.h‐1 for 60 min followed by 0.45 mg.kg‐1.h‐1 over 315 min)
Number of subjects: 8
Study 8548055 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 8
Study 8548055 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose progesterone
Number of subjects: 8
Study 2122514 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 30
Study 2122514 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue‐type plasminogen activator (rtPA)
Number of subjects: 30
Study 2122514 — intervention group
Group type: COMPARATOR
Intervention: Comparison of rtPA and SK
Number of subjects: 30
Study 417615 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 120
Study 417615 — intervention group
Group type: COMPARATOR
Intervention: Mazindol
Number of subjects: 120
Study 417615 — intervention group
Group type: COMPARATOR
Intervention: Diethylpropion
Number of subjects: 120
Study 417615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30721997 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human lactoferrin
Number of subjects: 54
Study 30721997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 28118454 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 161
Study 28118454 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 161
Study 28118454 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment during washout
Number of subjects: 161
Study 26414234 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial electrotherapy stimulation (CES) at 2 mA for 20 minutes, five days a week for 2 weeks
Number of subjects: 16
Study 26414234 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (CES device turned on and off)
Number of subjects: 16
Study 23472927 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose intravenous cephalothin
Number of subjects: 102
Study 23472927 — intervention group
Group type: COMPARATOR
Intervention: Single-dose intravenous cephalothin plus oral amoxicillin/clavulanate for 7 days
Number of subjects: 102
Study 21193063 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing (AP) with left ventricular (LV) pacing
Number of subjects: 28
Study 21193063 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing (AP) with biventricular (BiV) pacing
Number of subjects: 28
Study 21193063 — intervention group
Group type: COMPARATOR
Intervention: Atrial sensing (AS) with left ventricular (LV) pacing
Number of subjects: 28
Study 21193063 — intervention group
Group type: COMPARATOR
Intervention: Atrial sensing (AS) with biventricular (BiV) pacing
Number of subjects: 28
Study 19183157 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 60 mg
Number of subjects: 4092
Study 19183157 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 90 mg
Number of subjects: 4092
Study 19183157 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 4092
Study 19183157 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 4092
Study 19183157 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 90 mg in moderate-to-severe EO
Number of subjects: 4092
Study 17062036 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-band ultraviolet B (BB-UVB) phototherapy
Number of subjects: 32
Study 15016561 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% QD
Number of subjects: 379
Study 15016561 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% BID
Number of subjects: 379
Study 15016561 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% BID
Number of subjects: 379
Study 11843388 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (50 microg)
Number of subjects: 370
Study 11843388 — intervention group
Group type: COMPARATOR
Intervention: Vaginal dinoprostone
Number of subjects: 370
Study 9542607 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with birch-pollen extract
Number of subjects: 4
Study 9542607 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 4
Study 7929825 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive exercise under normoxic conditions
Number of subjects: 6
Study 7929825 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive exercise under hypoxic conditions
Number of subjects: 6
Study 7929825 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive exercise
Number of subjects: 6
Study 3349417 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein A treatment (Prosorba column containing 50 or 200 mg protein A, administered 12 times either once per week or three times per week)
Number of subjects: 7
Study 3349417 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein A treatment (Prosorba column)
Number of subjects: 7
Study 29231046 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy during the active phase of labor
Number of subjects: 40
Study 28882371 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.1 mg kg−1) and midazolam (1.0 mg kg−1)
Number of subjects: 9
Study 28882371 — intervention group
Group type: COMPARATOR
Intervention: Alfaxalone (15 mg kg−1) and midazolam (1.0 mg kg−1)
Number of subjects: 9
Study 26076302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice spray
Number of subjects: 22
Study 26076302 — intervention group
Group type: COMPARATOR
Intervention: Water spray
Number of subjects: 22
Study 23873559 — intervention group
Group type: EXPERIMENTAL
Intervention: Added P from KH2PO4 at levels of 0, 0.7, 1.4, or 2.1 g/kg of diet
Number of subjects: 96
Study 23873559 — intervention group
Group type: EXPERIMENTAL
Intervention: Added phytase at levels of 500 or 1,000 phytase units
Number of subjects: 96
Study 23873559 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 5 g of highly soluble calcium (HSC)
Number of subjects: 96
Study 23873559 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 1,000 units of added phytase
Number of subjects: 96
Study 23873559 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytase-related efficiency of ileal digestible P utilization for bone mineralization
Number of subjects: 96
Study 23873559 — intervention group
Group type: COMPARATOR
Intervention: KH2PO4 without added phytase
Number of subjects: 96
Study 20946200 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT
Number of subjects: 110
Study 20946200 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual CBT
Number of subjects: 110
Study 20946200 — intervention group
Group type: COMPARATOR
Intervention: Meta-analysis of individual CBT vs group CBT
Number of subjects: 110
Study 19688036 — intervention group
Group type: EXPERIMENTAL
Intervention: SODIS intervention with a mean compliance of 32.1%.
Number of subjects: 725
Study 19688036 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SODIS intervention).
Number of subjects: 725
Study 19688036 — intervention group
Group type: EXPERIMENTAL
Intervention: SODIS intervention.
Number of subjects: 725
Study 19688036 — intervention group
Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 725
Study 16820626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve repair with CABG (repair group, n=50)
Number of subjects: 107
Study 16820626 — intervention group
Group type: COMPARATOR
Intervention: CABG only (CABG group, n=57)
Number of subjects: 107
Study 16820626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve repair with CABG (repair group)
Number of subjects: 107
Study 16820626 — intervention group
Group type: COMPARATOR
Intervention: CABG only (CABG group)
Number of subjects: 107
Study 16820626 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 107
Study 15582348 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-treatment program with additional information on recognizing prodromal signs and doubling inhaled corticosteroids (ICS) during one week
Number of subjects: 29
Study 15582348 — intervention group
Group type: COMPARATOR
Intervention: Structured information on asthma, symptoms, and medication
Number of subjects: 29
Study 11393635 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-monitored exercise (ME)
Number of subjects: 45
Study 11393635 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-coached exercise (CE)
Number of subjects: 45
Study 9416012 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop-jumps from a height of 0.28 m
Number of subjects: 8
Study 9416012 — intervention group
Group type: EXPERIMENTAL
Intervention: Pendulum rebounds
Number of subjects: 8
Study 9416012 — intervention group
Group type: COMPARATOR
Intervention: Standing condition
Number of subjects: 8
Study 9416012 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop-jumps
Number of subjects: 8
Study 9416012 — intervention group
Group type: EXPERIMENTAL
Intervention: Pendulum exercises
Number of subjects: 8
Study 9416012 — intervention group
Group type: EXPERIMENTAL
Intervention: Both exercise regimens
Number of subjects: 8
Study 11767316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sufentanil (150 micrograms)
Number of subjects: 60
Study 11767316 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil (150 micrograms)
Number of subjects: 60
Study 11767316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (150 micrograms)
Number of subjects: 60
Study 11767316 — intervention group
Group type: COMPARATOR
Intervention: Control (no sufentanil)
Number of subjects: 60
Study 3793280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (4-8 micrograms/kg)
Number of subjects: 16
Study 3793280 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (10 mg)
Number of subjects: 16
Study 3793280 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Nisoldipine + Metoprolol)
Number of subjects: 16
Study 3793280 — intervention group
Group type: EXPERIMENTAL
Intervention: Order of administration (Nisoldipine added to Metoprolol)
Number of subjects: 16
Study 3793280 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic exercise
Number of subjects: 16
Study 29359848 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based treatment (0.3 g glucose/kg body-weight)
Number of subjects: 30
Study 29359848 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of 12 g glucose
Number of subjects: 30
Study 29359848 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of 30 g glucose
Number of subjects: 30
Study 25989706 — intervention group
Group type: EXPERIMENTAL
Intervention: IVB + TRP group
Number of subjects: 38
Study 25989706 — intervention group
Group type: COMPARATOR
Intervention: IVB group
Number of subjects: 38
Study 25141250 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 104
Study 25141250 — intervention group
Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 104
Study 25141250 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 104
Study 22321758 — intervention group
Group type: EXPERIMENTAL
Intervention: Home rehabilitation program once a month for 6 months with audiovisual materials
Number of subjects: 60
Study 22321758 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 22321758 — intervention group
Group type: EXPERIMENTAL
Intervention: Home rehabilitation program
Number of subjects: 60
Study 20478741 — intervention group
Group type: EXPERIMENTAL
Intervention: eszopiclone 3mg
Number of subjects: 60
Study 20478741 — intervention group
Group type: EXPERIMENTAL
Intervention: fluoxetine
Number of subjects: 60
Study 20478741 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia Severity Index (ISI)
Number of subjects: 60
Study 20478741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17462639 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist trigger after cotreatment with GnRH antagonist
Number of subjects: 66
Study 17462639 — intervention group
Group type: COMPARATOR
Intervention: hCG trigger after dual pituitary suppression with a GnRH agonist
Number of subjects: 66
Study 15982504 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin C administration
Number of subjects: 44
Study 15982504 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy (Control)
Number of subjects: 44
Study 11865815 — intervention group
Group type: EXPERIMENTAL
Intervention: TMTX/5-FU/LV (TMTX 110 mg/m2 i.v. followed by LV 200 mg/m2/5-FU 500 mg/m2 plus oral LV rescue)
Number of subjects: 746
Study 11865815 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV (5-FU 600 mg/m2 in Europe and 500 mg/m2 in USA)
Number of subjects: 746
Study 11865815 — intervention group
Group type: EXPERIMENTAL
Intervention: TMTX/5-FU/LV
Number of subjects: 746
Study 11865815 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 746
Study 11100888 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II lens (Soflens 66)
Number of subjects: 22
Study 11100888 — intervention group
Group type: EXPERIMENTAL
Intervention: Group IV lens (Acuvue)
Number of subjects: 22
Study 8732588 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol treatment
Number of subjects: 173
Study 8732588 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 173
Study 1414927 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg once daily
Number of subjects: 42
Study 1414927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 2861844 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg twice daily)
Number of subjects: 12
Study 2861844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 12
Study 2861844 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine and Cimetidine (in combination)
Number of subjects: 12
Study 2861844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30207844 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous diffusion of oxygen (CDO) therapy
Number of subjects: 146
Study 30207844 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 146